Denali Therapeutics Inc — Balance Sheet (NASDAQ:DNLI) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 1.6 B1.4 B1.46 B1.15 B1.37 B1.14 B Total liabilities 453.75 M441.87 M417.81 M122.96 M144.5 M131.09 M Total equity 1.15 B962.29 M1.04 B1.03 B1.23 B1.01 B Total liabilities & shareholders' equities 1.6 B1.4 B1.46 B1.15 B1.37 B1.14 B Total debt —————— Net debt ——————

Haberler

DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus

Wolfe Research, Denali Therapeutics hissesine Peerperform verdi

Wolfe Research initiates Denali Therapeutics stock with Peerperform

Denali Therapeutics Inc. (DNLI) Presents at 22nd Annual WORLDSymposium - Slideshow (NASDAQ:DNLI) 2026-02-06

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call - Slideshow (NASDAQ:DNLI) 2026-02-05

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Denali, WORLDSymposium’da nadir hastalık tedavilerine ilişkin klinik verileri sunacak

Denali to present clinical data on rare disease therapies at WORLDSymposium

Denali Therapeutics hissesi, Goldman Sachs’ta ilaç geliştirme ilerlemesiyle Al notunu korudu

Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript